KW-1062の内科領域における基礎的ならびに臨床的検討

DOI Web Site

書誌事項

タイトル別名
  • LABORATORY AND CLINICAL STUDIES ON KW-1062 IN INTERNAL FIELD
  • KW 1062 ノ ナイカ リョウイキ ニ オケル キソテキ ナラビニ リンシ

この論文をさがす

抄録

Some investigations were made on the clinical application of KW-1062 and the following results were obtained.<BR>1. Antibacterial activity of KW-1062 against Serratia was nearly the same as that of gentamicin. Cross-resistance between KW-1062 and gentamicin was observed in some of these strains.<BR>2. The peak serum level of KW-1062 in a patient of renal sufficency with pyelonephritis was at 4.3 μg/ml 1 hour after intramuscular administration of 60 mg dose.<BR>The urinary recovery of KW-1062 within 6 hours was 67.8% of the dose.<BR>3. Clinical result of KW-1062 was effective in 9 (64.3%) out of 14 patients.<BR>4. Elevation of S-GOT, S-GPT and BUN was encountered in some patients.However, these results might not be due to the administration of KW-1062, because antitumor agents or the blood transfusion had been applied to the patients suffering from underlying diseases such as malignant tumor, peritonitis or leukemia. No other adverse reactions were obseved.<BR>5. KW-1062 was administered concurrently with cephalosporins or penicillins to the patients who did not respond to those drugs. Satisfactory clinical responses were observed in 2 cases. With regard to these combination therapy, further investigations are required.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ